Compounds > laninamivir
Page last updated: 2024-09-27

laninamivir

Description

laninamivir: an antiviral agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID502272
CHEMBL ID466246
CHEBI ID177801
SCHEMBL ID12284832
MeSH IDM0543369

Synonyms (45)

Synonym
CHEBI:177801
(2r,3r,4s)-3-acetamido-4-(diaminomethylideneamino)-2-[(1r,2r)-2,3-dihydroxy-1-methoxypropyl]-3,4-dihydro-2h-pyran-6-carboxylic acid
laninamivir (cs-8958)
(2r,3r,4s)-3-acetamido-2-[(1r,2r)-2,3-dihydroxy-1-methoxy-propyl]-4-guanidino-3,4-dihydro-2h-pyran-6-carboxylic acid
5-acetylamino-4-(diaminomethyl-amino)-6-(2,3-dihydroxy-1-methoxy-propyl)-5,6-dihydro-4h-pyran-2-carboxylic acid
laninamivir
r-125489
203120-17-6
D09410
laninamivir (inn)
5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-7-o-methyl-d-glycero-d-galacto-non-2-enonic acid
r 125489
bdbm50009296
CHEMBL466246
A814430
(4s,5r,6r)-5-acetamido-4-guanidino-6-((1r,2r)-2,3-dihydroxy-1-methoxypropyl)-5,6-dihydro-4h-pyran-2-carboxylic acid
b408iw3gl5 ,
laninamivir [inn:jan]
(4s,5r,6r)-5-acetamido-4-carbamimidamido-6-((1r,2r)-3-hydroxy-2-methoxypropyl)-5,6-dihydro-4h-pyran-2-carboxylic acid
unii-b408iw3gl5
BCP9000836
BCPP000190
AKOS015850995
laninamivir [mart.]
laninamivir [who-dd]
laninamivir [mi]
laninamivir [inn]
SCHEMBL12284832
(2r,3r,4s)-3-acetamido-2-((1r,2r)-2,3-dihydroxy-1-methoxypropyl)-4-guanidino-3,4-dihydro-2h-pyran-6-carboxylic acid ,
C21557
d-glycero-d-galacto-non-2-enonic acid, 5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-7-o-methyl-
lani
DB12791
AKOS032947260
DTXSID60942457
EX-A4019
BCP27633
Q6487096
CS-0003575
MS-25321
HY-14818
r 125489r 125489
GLXC-15033
AC-36457
(4s,5r,6r)-5-acetamido-4-guanidino-6- ((1r,2r)-2,3-dihydroxy-1-methoxypropyl)-5,6-dihydro-4h-pyran-2-carboxylic acid

Research Excerpts

Overview

ExcerptReference
"Laninamivir octanoate is a recently developed inhaled neuraminidase inhibitor for treating influenza virus infection. "( Fujii, T; Higashiguchi, M; Matsumoto, T, 2018)
"Laninamivir is a novel long-lasting NAI that has demonstrated in vitro activity against influenza A and B viruses, and its prodrug (laninamivir octanoate) is in phase II clinical trials in the United States and other countries."( Abed, Y; Boivin, G; Desrochers, FM; Hamilton, S; Luttick, A; Pryor, MJ; Samson, M; Tucker, SP, 2014)
"Laninamivir is a 7-methoxy derivative of zanamivir, but a single dose is effective when taken as the laninamivir octanoate prodrug."( Barrett, S; McKimm-Breschkin, JL, 2015)
"Laninamivir is a long-acting antiviral requiring only a single dose for the treatment of influenza infection, making it an attractive alternative to existing neuraminidase inhibitors that require multiple doses over many days. "( Hurt, AC; Margo, K; Morton, DA; Mosse, J; Oh, DY; Panozzo, J; Piedrafita, D, 2015)
"Laninamivir octanoate is an inhaled drug with unique characteristics."( Ikematsu, H; Kawai, N, 2011)

Effects

ExcerptReference
"Laninamivir octanoate has displayed clinical efficacy comparable to that of oseltamivir and zanamivir against the H1N1 pandemic influenza strain from 2009, seasonal H3N2 influenza and influenza B viruses."( Ikematsu, H; Kawai, N, 2011)

Drug Classes (1)

ClassDescription
acetamidesCompounds with the general formula RNHC(=O)CH3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuraminidase Influenza A virus (A/Wilson-Smith/1933(H1N1))IC50 (µMol)0.01150.00000.503510.0000AID542945; AID542946; AID542947; AID542948; AID542949; AID542950; AID542951; AID542952; AID542953; AID542954; AID542955; AID542956; AID542957; AID542958; AID542959; AID542960; AID542961; AID542962; AID542963; AID542964; AID542965; AID542966; AID542967; AID542968; AID542969; AID542970; AID542971; AID542995; AID542996; AID542997; AID542998; AID542999; AID543000; AID543001; AID543002; AID543003; AID543004; AID543006; AID543007; AID543183; AID543184; AID543186; AID543187
Neuraminidase Influenza A virus (A/RI/5+/1957(H2N2))IC50 (µMol)3.10000.80001.76673.1000AID1129834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (202)

Assay IDTitleYearJournalArticle
AID567610Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID543207Inhibition of Vibrio cholerae neuraminidase by spectrofluorometric analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID573458Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1))2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.
AID352031Inhibition of Influenza A virus (A/Puerto Rico/8/34(H1N1)) sialidase2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID1212209Drug level in primary cultured BALB/c mouse airway epithelial cells treated with laninamivir octanoate at 50 uM measured up 60 to 90 mins by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID567612Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1212192AUClast in BALB/cAnNCrlCrlj mouse plasma treated with laninamivir octanoate at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID573448Drug level in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered as [14C]labeled compound intranasally as single dose measured 120 hrs post dose2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.
AID542977Inhibition of Influenza B virus (B/Akita/9/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542955Inhibition of Influenza A virus (A/Yamagata/83/2006(H1N1)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542967Inhibition of Influenza A virus (A/Yamagata/2/2002(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542981Inhibition of Influenza B virus (B/Aichi/3/2006(Victoria)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567607Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542948Inhibition of Influenza A virus (A/Shiga/1/2002(H1N1)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567590Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567715Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID352033Inhibition of Influenza A virus (A/Singapore/1/1957 (H2N2)) sialidase2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID542962Inhibition of Influenza A virus (A/New York/55/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567597Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567591Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID543188Ratio of IC50 for Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) neuraminidase N294S mutant to IC50 for Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) wild type neuraminidase2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542951Inhibition of Influenza A virus (A/Saitama/78/2003(H1N1)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567600Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID573441Half life in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered as [14C]labeled compound intranasally as single dose2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.
AID352035Inhibition of Influenza A virus (A/Kitakyushu/159/93(H3N2)) sialidase2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID567601Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567615Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542979Inhibition of Influenza B virus (B/Yamagata/145/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567711Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567617Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1212174Cmax in BALB/cAnNCrlCrlj mouse plasma at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID567707Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542947Inhibition of Influenza A virus (A/New Caledonia/20/1999(H1N1)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543185Ratio of IC50 for Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) neuraminidase E119V mutant to IC50 for Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) wild type neuraminidase2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542998Inhibition of Influenza A virus (A/duck/Alberta/60/1976(H12N5)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1212165Drug uptake in BALB/cAnNCrlCrlj mouse epithelial lining fluid treated with laninamivir octanoate at 0.5 umol/kg administered intranasally measured at 24 hrs by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID543208Inhibition of Clostridium perfringens neuraminidase by spectrofluorometric analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542975Inhibition of Influenza B virus (B/Shiga/17/2002(Victoria)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542970Inhibition of Influenza A virus (A/Tokushima/1/2005(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567603Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID543211Cytotoxicity against dog MDCK cells by MTT calorimetric assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1129833Inhibition of Influenza A virus (A/RI/5+/1957(H2N2)) recombinant neuraminidase using MUNANA as substrate at 100 uM after 30 mins2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Benzophenone C-glucosides and gallotannins from mango tree stem bark with broad-spectrum anti-viral activity.
AID567713Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1))virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1212194Drug uptake in BALB/cAnNCrlCrlj mouse epithelial lining fluid at 0.5 umol/kg administered intranasally measured at 4 hrs by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID543206Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) assessed as inhibition of viral replication by plaque reduction assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567703Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542995Inhibition of Influenza A virus (A/R(duck/Mongolia/54/01-duck/Mongolia/47/01)(H5H1)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543190Inhibition of Influenza B virus (B/Yokohama/UT3318/2005)) neuraminidase N294S mutant after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542976Inhibition of Influenza B virus (B/Yamagata/15/2002(Victoria)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543183Inhibition of Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) wild type neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567609Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542950Inhibition of Influenza A virus (A/Yamagata/57/2002(H1N1)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567722Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1212183Elimination half life in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID567724Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542996Inhibition of Influenza A virus (A/duck/Hokkaido/84/2002(H5N3)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567705Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1212173Elimination half life in BALB/cAnNCrlCrlj mouse epithelial lining fluid treated with laninamivir octanoate at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID567614Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1212195Drug uptake in BALB/cAnNCrlCrlj mouse epithelial lining fluid treated with laninamivir octanoate at 0.5 umol/kg administered intranasally measured at 4 hrs by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID567593Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1212171Cmax in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID567608Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567613Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1212191AUClast in BALB/cAnNCrlCrlj mouse plasma at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID542997Inhibition of Influenza A virus (A/turkey/Ontario/6,118/1968(H8N4)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543192Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 69 ug/kg, itn administered 4 hrs pre-infection and at 4 hrs and 18 hrs post-infection up to 10 days2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543003Inhibition of Influenza A virus (A/Yokohama/67/2006(clone 1)(H1N1)) wild type neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567725Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542958Inhibition of Influenza A virus (A/Kitakyushu/159/1993(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543006Inhibition of Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) wild type neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542983Inhibition of Influenza B virus (B/Mie/1/1993(Yamagata)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542978Inhibition of Influenza B virus (B/Tokushima/1/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543187Inhibition of Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) neuraminidase N294S mutant after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567716Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567599Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542980Inhibition of Influenza B virus (B/Yamagata/398/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543212Cytotoxicity against human MOLT4 cells by MTT calorimetric assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1212184Elimination half life in BALB/cAnNCrlCrlj mouse lung treated with laninamivir octanoate at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID542946Inhibition of Influenza A virus (A/Yamagata/32/1989(H1N1)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567594Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1212186Elimination half life in BALB/cAnNCrlCrlj mouse plasma treated with laninamivir octanoate at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID1212168Drug uptake in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered intranasally measured at 24 hrs by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID567710Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567618Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567589Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542968Inhibition of Influenza A virus (A/Saitama/80/2003(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1857995Inhibition of influenza virus neuraminidase2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Sialidase Inhibitors with Different Mechanisms.
AID567723Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542988Inhibition of Influenza B virus (B/Yamagata/87/2004(Yamagata)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543186Inhibition of Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) wild type neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567616Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1212170Cmax in BALB/cAnNCrlCrlj mouse epithelial lining fluid treated with laninamivir octanoate at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID567714Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567721Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567719Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542989Inhibition of Influenza B virus (B/Aichi/186/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567605Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567727Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID352045Antiviral activity against Influenza A virus (A/R(duck/Mongolia/54/01-duck/Mongolia/47/01) (H5N1)) assessed viral plaque reduction2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID1212196Drug uptake in BALB/cAnNCrlCrlj mouse plasma at 0.5 umol/kg administered intranasally measured after 8 hrs by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID352044Antiviral activity against Influenza B virus (B/Mie/1/93) assessed viral plaque reduction2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID542986Inhibition of Influenza B virus (B/Shizuoka/58/2004(Yamagata)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542945Inhibition of Influenza A virus (A/Puerto Rico/8/1934(H1N1)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567704Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1212182Elimination half life in BALB/cAnNCrlCrlj mouse epithelial lining fluid at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID542960Inhibition of Influenza A virus (A/Wellington/1/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID352036Inhibition of Influenza B virus (B/Mie/1/93) sialidase2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID567595Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542987Inhibition of Influenza B virus (B/Yamagata/85/2004(Yamagata)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1212177Tmax in BALB/cAnNCrlCrlj mouse epithelial lining fluid treated with laninamivir octanoate at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID567708Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID352043Antiviral activity against Influenza A virus (A/Kitakyushu/159/93(H3N2)) assessed viral plaque reduction2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID1212180Tmax in BALB/cAnNCrlCrlj mouse plasma at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID352032Inhibition of Influenza A virus (A/Yamagata/32/1989 (H1N1)) sialidase2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID542949Inhibition of Influenza A virus (A/Yamagata/3/2002(H1N1)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542990Inhibition of Influenza B virus (B/Saitama/01/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID352034Inhibition of Influenza A virus (A/Aichi/2/1968(H3N2)) sialidase2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID1212190AUClast in BALB/cAnNCrlCrlj mouse lung treated with laninamivir octanoate at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID1212169Cmax in BALB/cAnNCrlCrlj mouse epithelial lining fluid at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID567709Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID352041Antiviral activity against Influenza A virus (A/Singapore/1/1957 (H2N2)) assessed viral plaque reduction2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID352039Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed viral plaque reduction2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID352042Antiviral activity against Influenza A virus (A/Aichi/2/1968(H3N2)) assessed viral plaque reduction2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID542959Inhibition of Influenza A virus (A/Wyoming/03/2003(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542964Inhibition of Influenza A virus (A/Wisconsin/67/2005(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1212193Cmax in BALB/cAnNCrlCrlj mouse lung treated with laninamivir octanoate at 0.5 umol/kg administered intranasally measured at 24 hrs2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID1212167Elimination half life in human treated with laninamivir octanoate administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID542973Inhibition of Influenza B virus (B/Malaysia/2506/2004(Victoria)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1212188AUClast in BALB/cAnNCrlCrlj mouse epithelial lining fluid treated with laninamivir octanoate at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID567712Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID543193Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 69 ug/kg, itn administered 4 hrs pre-infection and at 4 hrs and 18 hrs post-infection up to 20 days2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543001Inhibition of Influenza A virus (A/duck/Ukraine/1/1963(H3N8)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542971Inhibition of Influenza A virus (A/Saitama/07/2006(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542982Inhibition of Influenza B virus (B/Saitama/01/2006(Victoria)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543182Ratio of IC50 for Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) neuraminidase R292K mutant to IC50 for Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) wild type neuraminidase2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1212163Lipophilicity, log D of the compound at pH 7.42013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID542991Inhibition of Influenza B virus (B/Sapporo/29/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1212187AUClast in BALB/cAnNCrlCrlj mouse epithelial lining fluid at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID352040Antiviral activity against Influenza A virus (A/Yamagata/32/1989 (H1N1)) assessed viral plaque reduction2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID567720Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID573277Cmax in BALB/cAnNCrlCrlj mouse lung assessed as compound concentration per gram of tissue at 0.5 umol/kg administered as [14C]labeled compound intranasally as single dose2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.
AID542969Inhibition of Influenza A virus (A/Osaka/56/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1212181Tmax in BALB/cAnNCrlCrlj mouse plasma treated with laninamivir octanoate at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID1212172Cmax in BALB/cAnNCrlCrlj mouse lung treated with laninamivir octanoate at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID542963Inhibition of Influenza A virus (A/Hiroshima/52/2005(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543184Inhibition of Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) neuraminidase E119V mutant after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1212175Cmax in BALB/cAnNCrlCrlj mouse plasma treated with laninamivir octanoate at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID1212166Tmax in human treated with laninamivir octanoate at 40 mg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID543005Ratio of IC50 for Influenza A virus (A/Yokohama/67/2006(clone 11)(H1N1)) neuraminidase H274Y mutant to IC50 for Influenza A virus (A/Yokohama/67/2006(clone 1)(H1N1)) wild type neuraminidase2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543002Inhibition of Influenza A virus (A/duck/Memphis/546/1974(H11N9)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID352046Antiviral activity against Tamiflu-resistant influenza A virus (A/Yokohama/67/2006 (H1N1)) assessed viral plaque reduction2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID542999Inhibition of Influenza A virus (A/duck/England/1/1956(H11N6)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID525069Half life in mouse2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID542993Inhibition of Influenza B virus (B/Yamagata/1/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567604Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567702Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme expressing wild type enzyme by NA-star substrate based chemi2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1212162Drug level in primary cultured BALB/c mouse airway epithelial cells treated with laninamivir octanoate at 50 uM measured at 24 hrs by LC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID542954Inhibition of Influenza A virus (A/Aichi/169/2005(H1N1)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542965Inhibition of Influenza A virus (A/Shiga/5/2002(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543209Inhibition of Newcastle disease virus neuraminidase by spectrofluorometric analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542972Inhibition of Influenza B virus (B/Brisbane/32/2002(Victoria) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542985Inhibition of Influenza B virus (B/Shiga/31/2002(Yamagata)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1212189AUClast in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID542956Inhibition of Influenza A virus (A/Singapore/1/1957(H2N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542953Inhibition of Influenza A virus (A/Okinawa/42/2004(H1N1)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542984Inhibition of Influenza B virus (B/Shanghai/361/2002(Yamagata)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567611Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567592Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567718Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID352038Inhibition of Tamiflu-resistant Influenza A virus (A/Yokohama/67/2006 (H1N1)) sialidase2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID573278Tmax in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered as [14C]labeled compound intranasally as single dose2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.
AID567602Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID543210Cytotoxicity against human HeLa cells by MTT calorimetric assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1212178Tmax in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID567598Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567596Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567588Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542966Inhibition of Influenza A virus (A/Yamagata/1/2002(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543007Inhibition of Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) neuraminidase R292K mutant after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542992Inhibition of Influenza B virus (B/Tokushima/1/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542974Inhibition of Influenza B virus (B/Ohio/01/2005(Victoria)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1212176Tmax in BALB/cAnNCrlCrlj mouse epithelial lining fluid at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID543000Inhibition of Influenza A virus (A/seal/Massachusetts/1/1980(H7N7)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567726Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542957Inhibition of Influenza A virus (A/Aichi/2/1968(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542952Inhibition of Influenza A virus (A/Aichi/193/2004(H1N1)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID352047Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected mouse assessed as mouse survival at 0.2 umol/kg dosed intranasally 4 hrs before and 4 hrs, 17 hrs after viral infection measured 20 days post infection2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID543189Inhibition of Influenza B virus (B/Yokohama/UT2203/2005)) neuraminidase N294S mutant after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567587Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542994Inhibition of Influenza B virus (B/Yamagata/113/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567706Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567586Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1212179Tmax in BALB/cAnNCrlCrlj mouse lung treated with laninamivir octanoate at 0.5 umol/kg administered intranasally2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
AID352037Inhibition of Influenza A virus (A/R(duck/Mongolia/54/01-duck/Mongolia/47/01) (H5N1)) sialidase2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID1692537Oral bioavailability in rat2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
AID542961Inhibition of Influenza A virus (A/California/07/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567717Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567728Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID543004Inhibition of Influenza A virus (A/Yokohama/67/2006(clone 11)(H1N1)) neuraminidase H274Y mutant after 30 mins by fluorescence analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1129834Inhibition of Influenza A virus (A/RI/5+/1957(H2N2)) recombinant neuraminidase using MUNANA as substrate after 30 mins2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Benzophenone C-glucosides and gallotannins from mango tree stem bark with broad-spectrum anti-viral activity.
AID567606Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (102)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (2.94)29.6817
2010's85 (83.33)24.3611
2020's14 (13.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (14.56%)5.53%
Reviews13 (12.62%)6.00%
Case Studies4 (3.88%)4.05%
Observational3 (2.91%)0.25%
Other68 (66.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
CS-8958 - A Phase I, Double-blind, Placebo-controlled, Ascending, Multiple Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects.[NCT00995826]Phase 116 participants (Actual)Interventional2009-04-30Completed
Randomised, Parallel Dose, Phase 1/2 Safety and Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Naturally Acquired Influenza A or B[NCT02014649]Phase 1/Phase 215 participants (Actual)Interventional2013-11-30Terminated(stopped due to Study was terminated as per BARDA decision to terminate contract.)
ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA)[NCT05648448]Phase 2250 participants (Anticipated)Interventional2023-02-22Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate in Adults With Chronic Asthma[NCT02022761]Phase 132 participants (Actual)Interventional2013-10-31Completed
A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Arm Study to Investigate the Efficacy and Safety of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Symptomatic Influenza A or B Infection[NCT01793883]Phase 2639 participants (Actual)Interventional2013-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Time to Alleviation of Influenza Symptoms

Time to Alleviation of Influenza Symptoms

Time to alleviation of influenza will be assessed through Flu-iiQ (Influenza intensity and impact Questionnaire) and diary cards from Day 1 to 14. (NCT01793883)
Timeframe: Efficacy will be assessed over 14 days post-randomization.

Interventionhours (Median)
40 mg Laninamivir Octanoate DPI102.30
80 mg Laninamivir Octanoate DPI103.20
Placebo104.10

[back to top]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
zanamivir[no description available]medium980guanidinesantiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
zanamivir[no description available]medium9815guanidinesantiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
oseltamivir[no description available]medium510acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
oseltamivir[no description available]medium515acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
cs 8958[no description available]medium50fatty acid ester
tamiflu[no description available]medium20phosphate salt
bcx 1812[no description available]medium303-hydroxy monocarboxylic acid;
acetamides;
cyclopentanols;
guanidines		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
a 315675[no description available]medium20
gallic acid[no description available]medium10trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose[no description available]medium10gallate ester;
galloyl beta-D-glucose		anti-inflammatory agent;
antineoplastic agent;
geroprotector;
hepatoprotective agent;
plant metabolite;
radiation protective agent;
radical scavenger
theogallin[no description available]medium10gallate ester;
monocarboxylic acid;
tertiary alcohol
mangiferin[no description available]medium10C-glycosyl compound;
xanthones		anti-inflammatory agent;
antioxidant;
hypoglycemic agent;
plant metabolite
diclofenac[no description available]medium10amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
propafenone[no description available]medium10aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug
propantheline bromide[no description available]medium10xanthenes
gs 4071[no description available]medium20acetate ester;
amino acid;
cyclohexenecarboxylic acid;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
marine xenobiotic metabolite
2-deoxy-2,3-dehydro-n-acetylneuraminic acid[no description available]medium10N-acetylneuraminic acids
cyclohexene[no description available]medium10cycloalkene
peramivir[no description available]medium343
cyclopentane[no description available]medium313cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
berotek[no description available]medium10resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
dihydrostreptomycin sulfate[no description available]medium10
angiotensin amide[no description available]medium10oligopeptide
naratriptan[no description available]medium10heteroarylpiperidine;
sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
favipiravir[no description available]medium30hydroxypyrazine;
organofluorine compound;
primary carboxamide		anticoronaviral agent;
antiviral drug;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
pyrazines[no description available]medium30diazine;
pyrazines		Daphnia magna metabolite
acetaminophen[no description available]medium10acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
azathioprine[no description available]medium10aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
amantadine[no description available]medium20adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
cs 8958[no description available]medium82
ozone[no description available]medium10elemental molecule;
gas molecular entity;
reactive oxygen species;
triatomic oxygen		antiseptic drug;
disinfectant;
electrophilic reagent;
greenhouse gas;
mutagen;
oxidising agent;
tracer
pyruvaldehyde[no description available]medium102-oxo aldehyde;
propanals		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
adamantane[no description available]medium10adamantanes;
polycyclic alkane
caprylates[no description available]medium20fatty acid anion 8:0;
straight-chain saturated fatty acid anion		human metabolite;
Saccharomyces cerevisiae metabolite
octanoic acid[no description available]medium10medium-chain fatty acid;
straight-chain saturated fatty acid		antibacterial agent;
Escherichia coli metabolite;
human metabolite
acetamide[no description available]low00acetamides;
carboximidic acid;
monocarboxylic acid amide;
N-acylammonia
melatonin[no description available]low00acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
n-acetylserotonin[no description available]low00acetamides;
N-acylserotonin;
phenols		antioxidant;
human metabolite;
mouse metabolite;
tropomyosin-related kinase B receptor agonist
acetanilide[no description available]low00acetamides;
anilide		analgesic
n'-acetylspermine[no description available]low00acetamides;
acetylspermine		human metabolite
6-chloromelatonin[no description available]low00acetamides
6-hydroxymelatonin[no description available]low00acetamides;
tryptamines		metabolite;
mouse metabolite
acetarsol[no description available]low00acetamides;
anilide
4-(acetylamino)benzeneacetic acid[no description available]low00acetamides;
anilide
diatrizoic acid[no description available]low00acetamides;
benzoic acids;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
ci 994[no description available]low00acetamides;
benzamides;
substituted aniline		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
colchicine, (+-)-isomer[no description available]low00acetamides;
alkaloid;
aromatic ether;
carbotricyclic compound		microtubule-destabilising agent;
plant metabolite
gr 89696[no description available]low00acetamides
guanfacine[no description available]low00acetamides
hexamethylene bisacetamide[no description available]low00acetamides
acecainide[no description available]low00acetamides;
benzamides		anti-arrhythmia drug
phenacemide[no description available]low00acetamides
phenacetin[no description available]low00acetamides;
aromatic ether		cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug
practolol[no description available]low00acetamides;
ethanolamines;
propanolamine;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
beta-adrenergic antagonist
tropicamide[no description available]low00acetamides
talactoferrin alfa[no description available]low00acetamides
methacetin[no description available]low00acetamides;
aromatic ether
acedapsone[no description available]low00acetamides;
anilide;
secondary carboxamide;
sulfone		antimalarial;
antimicrobial drug
n-methylacetamide[no description available]low00acetamides;
monocarboxylic acid amide		metabolite
acetopyrrothine[no description available]low00acetamides;
dithiolopyrrolone antibiotic		angiogenesis inhibitor;
antibacterial agent;
antifungal agent;
antineoplastic agent;
bacterial metabolite;
chelator;
EC 2.7.7.6 (RNA polymerase) inhibitor;
marine metabolite;
protein synthesis inhibitor;
toxin
phenylbutyramide[no description available]low00acetamides
N-(2-methoxyphenyl)acetamide[no description available]low00acetamides;
methoxybenzenes
4-methylacetanilide[no description available]low00acetamides;
toluenes
arsthinol[no description available]low00acetamides;
anilide
nithiamide[no description available]low00acetamides;
aromatic amide
4'-(chloroacetyl)acetanilide[no description available]low00acetamides;
alpha-chloroketone;
aromatic ketone
4-chloroacetanilide[no description available]low00acetamides;
monochlorobenzenes
monoacetyldapsone[no description available]low00acetamides;
anilide;
secondary carboxamide;
sulfone
2-hydroxyacetanilide[no description available]low00acetamides;
phenols		anti-inflammatory agent;
antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
platelet aggregation inhibitor;
xenobiotic metabolite
3-hydroxyacetanilide[no description available]low00acetamides;
phenols		non-narcotic analgesic
n-ethylacetamide[no description available]low00acetamidesmetabolite
ethyl n-alpha-acetyl-tyrosinate[no description available]low00acetamides;
ethyl ester;
L-tyrosine derivative;
phenols
2-acetamidoethanethiol[no description available]low00acetamidesmetabolite
n,n-diethylphenylacetamide[no description available]low00acetamides
trimethylcolchicinic acid methyl ether[no description available]low00acetamides;
alkaloid;
carbotricyclic compound
dimethylacetamide[no description available]low00acetamides;
monocarboxylic acid amide		human metabolite
4-acetylaminofluorene[no description available]low00acetamides;
fluorenes		mitogen
ioxitalamic acid[no description available]low00acetamides;
benzoic acids;
dicarboxylic acid monoamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
lorcainide[no description available]low00acetamides
bidisomide[no description available]low00acetamides
n(4)-acetylsulfadiazine[no description available]low00acetamides;
pyrimidines;
sulfonamide		marine xenobiotic metabolite
6-sulfatoxymelatonin[no description available]low00acetamides
n-acetylaminoantipyrine[no description available]low00acetamides;
pyrazoles		drug metabolite;
marine xenobiotic metabolite
milnacipran[no description available]low00acetamides
N(4)-acetylsulfathiazole[no description available]low001,3-thiazoles;
acetamides;
sulfonamide		marine xenobiotic metabolite
disobutamide[no description available]low00acetamides
glycolamide[no description available]low00acetamides
n-acetylhistamine[no description available]low00acetamides;
imidazoles		human metabolite
n-acetyltryptamine[no description available]low00acetamides;
indoles
acamprosate[no description available]low00acetamides;
organosulfonic acid		environmental contaminant;
neurotransmitter agent;
xenobiotic
guanfacine hydrochloride[no description available]low00acetamidesgeroprotector
epanolol[no description available]low00acetamides
N-Acetylhomoveratrylamine[no description available]low00acetamides
s20098[no description available]low00acetamides
acetaminophen sulfate ester[no description available]low00acetamides;
aryl sulfate		drug metabolite
acetaminophen mercapturate[no description available]low00acetamides;
organic sulfide;
phenols;
S-substituted N-acetyl-L-cysteine		drug metabolite;
human urinary metabolite;
rat metabolite
4-(hydroxyphenyl)acetamide[no description available]low00acetamides
n-acetyltryptophanamide[no description available]low00acetamides;
L-tryptophan derivative;
primary carboxamide;
secondary carboxamide
n-acetyldopamine[no description available]low00acetamides;
catechols;
N-(fatty acyl)-dopamine;
secondary carboxamide		human urinary metabolite;
marine metabolite
ethyl-3-(n-n-butyl-n-acetyl)aminopropionate[no description available]low00acetamides;
ethyl ester;
tertiary carboxamide
n-acetylcytidine[no description available]low00acetamides;
cytidines;
secondary carboxamide		metabolite
2-iodomelatonin[no description available]low00acetamides
n-acetyltyramine[no description available]low00acetamides;
tyramines		animal metabolite;
Aspergillus metabolite;
bacterial metabolite;
marine metabolite;
quorum sensing inhibitor
luzindole[no description available]low00acetamides;
indoles		melatonin receptor antagonist
acetylphenylalanyl-prolyl-boroarginine[no description available]low00acetamides;
C-terminal boronic acid peptide;
guanidines		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor
n',n''-diacetylspermine[no description available]low00acetamides
acetyltaurine[no description available]low00acetamides;
organosulfonic acid		human blood serum metabolite;
human urinary metabolite
milnacipran hydrochloride[no description available]low00acetamides
n(4)-acetylsulfadimethoxine[no description available]low00acetamides;
pyrimidines;
sulfonamide		marine xenobiotic metabolite
monoacetylcadaverine[no description available]low00acetamides;
N-substituted cadaverine;
primary amino compound;
secondary carboxamide		human metabolite
N-hydroxy-2-phenylacetamide[no description available]low00acetamides
N-(1-phenylethyl)acetamide[no description available]low00acetamides;
secondary carboxamide
gamma-lumicolchicine[no description available]low00acetamides;
alkaloid;
carbotricyclic compound
1-(1-oxo-2-phenylethyl)-4-piperidinecarboxylic acid[no description available]low00acetamides
mr 16728[no description available]low00acetamides
linezolid[no description available]low00acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
ammodendrine[no description available]low00acetamides;
N-acylpiperidine;
piperidine alkaloid		plant metabolite;
teratogenic agent
N-[2-(4-methoxyphenyl)ethyl]acetamide[no description available]low00acetamides
N-(4-acetamidophenyl)-2-[(5-cyclopropyl-4-ethyl-1,2,4-triazol-3-yl)thio]acetamide[no description available]low00acetamides;
anilide
N-(4-{[2-(pyridin-3-yl)piperidin-1-yl]sulfonyl}phenyl)acetamide[no description available]low00acetamides;
piperidines;
pyridines;
sulfonamide
2-(4-methoxyphenyl)-N-(phenylmethyl)-N-propan-2-ylacetamide[no description available]low00acetamides
N-[4-(4-morpholinylazo)phenyl]acetamide[no description available]low00acetamides;
anilide
N-[[6-cyano-5-(ethylamino)-3-methyl-2-pyrazinyl]methyl]-N-phenylacetamide[no description available]low00acetamides;
anilide
N-[4-(5-bromo-2-thiophenyl)-2-thiazolyl]acetamide[no description available]low00acetamides;
aromatic amide
1-(1-azepanyl)-2-(4-bromophenyl)ethanone[no description available]low00acetamides
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-nitrophenyl)acetamide[no description available]low00acetamides
N-(5-chloro-2-hydroxyphenyl)-2-(4-methoxyphenyl)acetamide[no description available]low00acetamides
N-[3-(methylthio)-1,2,4-thiadiazol-5-yl]-2-phenylacetamide[no description available]low00acetamides
2-(3-acetamidophenoxy)-N-phenylacetamide[no description available]low00acetamides;
anilide
1-(4-methoxyphenyl)-N-(1,3,4-thiadiazol-2-yl)-1-cyclopentanecarboxamide[no description available]low00acetamides
N-[4-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide[no description available]low00acetamides;
anilide
N-[4-[2-[(6-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide[no description available]low00acetamides;
anilide
N-[3-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide[no description available]low00acetamides;
anilide
1-[[2-(3-bromo-4-methoxyphenyl)-1-oxoethyl]amino]-3-phenylthiourea[no description available]low00acetamides
4-(2,4-dichlorophenyl)-2-[(1-oxo-2-phenylethyl)amino]-3-thiophenecarboxamide[no description available]low00acetamides
2-acetamido-5-propyl-3-thiophenecarboxamide[no description available]low00acetamides;
aromatic amide
2-(4-methoxyphenyl)-N-[4-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]phenyl]acetamide[no description available]low00acetamides
2-(4-bromophenyl)-N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)acetamide[no description available]low00acetamides
N-[4-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]phenyl]-2-(2-methoxyphenyl)acetamide[no description available]low00acetamides
2-(4-chlorophenyl)-N-[4-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]phenyl]acetamide[no description available]low00acetamides
1-ethyl-3-[(1-oxo-2-phenylethyl)amino]thiourea[no description available]low00acetamides
N-[4-[[2-[1-(2-methoxyethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl]thio]phenyl]acetamide[no description available]low00acetamides;
anilide
2-phenyl-N-[2-(phenylmethylthio)ethyl]acetamide[no description available]low00acetamides
N-[2-(4-tert-butylphenoxy)ethyl]-2-(4-fluorophenyl)acetamide[no description available]low00acetamides
2-(4-chlorophenyl)-N-[4-(difluoromethylthio)phenyl]acetamide[no description available]low00acetamides
N-(4-acetamidophenyl)-2-[5-(1-piperidinylsulfonyl)-2-thiophenyl]acetamide[no description available]low00acetamides;
anilide
N-[4-[(2-furanylmethylamino)-sulfanylidenemethyl]phenyl]acetamide[no description available]low00acetamides;
anilide
acetylthiourea[no description available]low00acetamides;
thioureas
alpha-acetyllysine methyl ester[no description available]low00acetamides;
alpha-amino acid ester;
L-lysine derivative;
methyl ester;
primary amino compound
1-(2,6-dimethyl-1-piperidinyl)-2-phenylethanone[no description available]low00acetamides
N-(2-methoxyphenyl)-2-phenyl-2-(phenylthio)acetamide[no description available]low00acetamides
ici 199441[no description available]low00acetamides
N-[4-[[2-(4-acetamidoanilino)-5-nitro-4-pyrimidinyl]amino]phenyl]acetamide[no description available]low00acetamides;
anilide
1-[5-hydroxy-3-methyl-5-(3-pyridinyl)-4H-pyrazol-1-yl]-2-(4-methylphenyl)ethanone[no description available]low00acetamides
2-methoxy-N-[(4-methylphenyl)methyl]-2-phenylacetamide[no description available]low00acetamides
CID 3191469[no description available]low00acetamides;
anilide		anticoronaviral agent
CID 3198732[no description available]low00acetamides;
anilide		anticoronaviral agent
2-(4-ethoxyphenyl)-1-[5-hydroxy-3-methyl-5-(trifluoromethyl)-4H-pyrazol-1-yl]ethanone[no description available]low00acetamides
5-methoxycarbonylamino-n-acetyltryptamine[no description available]low00acetamides
2-(4-chlorophenyl)-3-methyl-N-(2-thiazolyl)butanamide[no description available]low00acetamides
N-[2-[1-(3,5-dimethyl-1-piperidinyl)-1-oxopropan-2-yl]oxyphenyl]acetamide[no description available]low00acetamides;
anilide
brl 52537[no description available]low00acetamides
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(-)-isomer[no description available]low00acetamides
levomilnacipran[no description available]low00acetamides
andarine[no description available]low00acetamides;
anilide
ro-28-1675[no description available]low00acetamides
holomycin[no description available]low00acetamides;
dithiolopyrrolone antibiotic		antibacterial agent;
antineoplastic agent;
bacterial metabolite;
chelator;
EC 2.7.7.6 (RNA polymerase) inhibitor;
marine metabolite
N-[1-(5,6-dicyano-3-methyl-2-pyrazinyl)ethyl]-N-phenylacetamide[no description available]low00acetamides;
anilide
trametinib[no description available]low00acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
n-(3-fluorophenyl)-1-((4-(((3s)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine[no description available]low00acetamides
2-acetamidoglucal[no description available]low00acetamides;
glycal derivative		metabolite
3-[1-[[1-(4-methoxyphenyl)cyclopropyl]-oxomethyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one[no description available]low00acetamides
3-[1-[[1-(4-methylphenyl)cyclopropyl]-oxomethyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one[no description available]low00acetamides
3-[1-[oxo-(1-phenylcyclopropyl)methyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one[no description available]low00acetamides
3-[1-[[1-(4-chlorophenyl)cyclopropyl]-oxomethyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one[no description available]low00acetamides
n(alpha)-acetylfusarinines[no description available]low002,5-diketopiperazines;
acetamides;
carboxylic ester;
homoallylic alcohol;
hydroxamic acid;
primary alcohol		siderophore
N-[2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]phenyl]acetamide[no description available]low00acetamides;
anilide
N-[5-[[2-(4-acetamidoanilino)-2-oxoethyl]thio]-1,3,4-thiadiazol-2-yl]-3-methoxybenzamide[no description available]low00acetamides;
anilide
N-[5-[[2-(4-acetamidoanilino)-2-oxoethyl]thio]-1,3,4-thiadiazol-2-yl]-5-bromo-2-furancarboxamide[no description available]low00acetamides;
anilide
N-[(2S,3S)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide[no description available]low00acetamides
KOM70144[no description available]low00acetamides;
benzamides;
naphthalenes;
secondary carboxamide		anticoronaviral agent;
protease inhibitor
n-(2-(5-methoxy-2-oxo-2,3-dihydro-1h-indol-3-yl)ethyl)acetamide[no description available]low00acetamides;
hydroxyindoles;
tryptamines		antineoplastic agent;
apoptosis inducer;
plant metabolite
N-[4-[2-(2-methoxyethylamino)-6H-1,3,4-thiadiazin-5-yl]phenyl]acetamide[no description available]low00acetamides;
anilide
N-[4-[2-(2-oxolanylmethylamino)-6H-1,3,4-thiadiazin-5-yl]phenyl]acetamide[no description available]low00acetamides;
anilide
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Liver Injury, Drug-Induced0low10
Adverse Drug Event0low10
Adverse Drug Reaction0low10
Anaphylactic Reaction0low10
Anaphylactoid Reaction0low10
Anaphylactoid Shock0low10
Anaphylaxis0low10
Asthma0medium11
Asthma, Bronchial0medium11
Autoimmune Chronic Hepatitis0low10
Autoimmune Hepatitis0low10
Avian Flu0low10
Avian Influenza0low10
Behavior Disorders0low10
Body Weight0low10
Bronchial Asthma0medium11
Chemical and Drug Induced Liver Injury0low10
Chemically-Induced Liver Toxicity0low10
Cholera Infantum0low10
Chronic Disease0medium11
Chronic Illness0medium11
Chronically Ill0medium11
Complications, Infectious Pregnancy0low10
Delirium0low10
Delirium of Mixed Origin0low10
Diagnosis, Psychiatric0low10
Disease Models, Animal0low40
Drop Attack0low10
Drug Side Effects0low10
Drug Toxicity0low10
Drug-Induced Acute Liver Injury0low10
Drug-Induced Liver Disease0low10
Drug-Induced Liver Injury0low10
Drug-Related Side Effects and Adverse Reactions0low10
Experimental Lung Inflammation0low10
Fainting0low10
Fever0medium93
Fowl Plague0low10
Functional Gastrointestinal Disorders0low10
Gastrointestinal Diseases0low10
Gastrointestinal Disorders0low10
Gastrointestinal Disorders, Functional0low10
Grippe0medium6813
Hepatitis, Autoimmune0low10
Hepatitis, Drug-Induced0low10
Hepatitis, Toxic0low10
Human Flu0medium6813
Human Influenza0medium6813
Icterus0low10
Infections, Orthomyxoviridae0low80
Infections, Orthomyxovirus0low80
Infectious Pregnancy Complications0low10
Inflammation0low10
Influenza0medium6813
Influenza in Birds0low10
Influenza in Humans0medium6813
Influenza, Avian0low10
Influenza, Human0medium6813
Innate Inflammatory Response0low10
Jaundice0low10
Jaundice, Hemolytic0low10
Kidney Failure0medium11
Kidney Insufficiency0medium11
Liver Injury, Drug-Induced0low10
Liver Injury, Drug-Induced, Acute0low10
Lobar Pneumonia0low10
Lung Inflammation0low10
Maternal Sepsis0low10
Mental Disorders0low10
Mental Disorders, Severe0low10
Mental Illness0low10
Nervous System Diseases0low10
Nervous System Disorders0low10
Neurologic Disorders0low10
Neurological Disorders0low10
Orthomyxoviridae Infections0low80
Orthomyxovirus Infections0low80
Pneumonia0low10
Pneumonia, Lobar0low10
Pneumonia, Viral0low10
Pneumonitis0low10
Pregnancy0medium21
Pregnancy Complications, Infectious0low10
Pregnancy, Infectious Complications0low10
Presyncope0low10
Psychiatric Diagnosis0low10
Psychiatric Diseases0low10
Psychiatric Disorders0low10
Psychiatric Illness0low10
Pulmonary Inflammation0low10
Pyrexia0medium93
Renal Failure0medium11
Renal Insufficiency0medium11
Sepsis during Pregnancy0low10
Sepsis in Pregnancy0low10
Shock, Anaphylactic0low10
Side Effects of Drugs0low10
Subacute Delirium0low10
Swine Influenza0low80
Syncopal Episode0low10
Syncopal Vertigo0low10
Syncope0low10
Syncope, Cardiogenic0low10
Syncope, Carotid Sinus0low10
Syncope, Convulsive0low10
Syncope, Deglutitional0low10
Syncope, Effort0low10
Syncope, Hyperventilation0low10
Syncope, Micturition0low10
Syncope, Postural0low10
Syncope, Situational0low10
Syncope, Stokes-Adams0low10
Syncope, Tussive0low10
Toxic Hepatitis0low10
Toxicity, Drug0low10

Research Highlights

Safety/Toxicity (4)

ArticleYear
The safety and efficacy of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate for Inhalation Suspension Set in children under the age of 5 in a post-marketing surveillance.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, Volume: 27, Issue: 10		2021
Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews.
Scientific reports, 02-20, Volume: 10, Issue: 1		2020
Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
Scandinavian journal of infectious diseases, Volume: 45, Issue: 6		2013
Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance.
International journal of antimicrobial agents, Volume: 40, Issue: 5		2012
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (7)

ArticleYear
Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects.
Antimicrobial agents and chemotherapy, Volume: 62, Issue: 1		2018
Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection.
Drug metabolism and pharmacokinetics, Volume: 28, Issue: 5		2013
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
Drug metabolism and disposition: the biological fate of chemicals, Volume: 41, Issue: 1		2013
Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.
Antimicrobial agents and chemotherapy, Volume: 56, Issue: 7		2012
Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.
Journal of clinical pharmacology, Volume: 51, Issue: 2		2011
Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats.
Xenobiotica; the fate of foreign compounds in biological systems, Volume: 40, Issue: 3		2010
Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers.
Journal of clinical pharmacology, Volume: 50, Issue: 11		2010
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (2)

ArticleYear
Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
European journal of medicinal chemistry, Aug-15, Volume: 200		2020
Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats.
Xenobiotica; the fate of foreign compounds in biological systems, Volume: 40, Issue: 3		2010
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (3)

ArticleYear
Association between anaphylaxis and anti-influenza drug use: An analysis of the Japanese Adverse Drug Event Report database.
Drug discoveries & therapeutics, Volume: 15, Issue: 3		2021
Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects.
Antimicrobial agents and chemotherapy, Volume: 62, Issue: 1		2018
Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers.
Journal of clinical pharmacology, Volume: 50, Issue: 11		2010
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]